Director at $CVRX buys 46,800 shares in insider purchase at Quiver Quantitative

A recent insider purchase has garnered attention as Mudit K. Jain, a director at $CVRX, acquired 46,800 shares of the company on 02-20-2026 for an estimated $297,591. This transaction, revealed through a recent SEC filing and reported by Quiver Quantitative, resulted in an approximate 5.0% increase in Jain’s holdings, bringing the total number of shares in this class owned by Jain to 980,183.

Over the past 6 months, $CVRX insiders have engaged in open-market trading for $CVRX stock on 8 occasions. Among these trades, 2 were purchases, while 6 were sales. Notably, Johnson & Johnson made no purchases but sold 62,569 shares, amounting to an estimated $637,001. On the other hand, Mudit K. Jain conducted 2 purchases, buying 47,400 shares for around $300,376 and refraining from any sales.

In terms of hedge fund activity, there have been noticeable shifts, with 36 institutional investors adding shares of $CVRX stock to their portfolios, while 54 reduced their positions in the latest quarter. Among the key moves, Silvercrest Asset Management Group LLC added 275,263 shares (+76.6%) in Q4 2025, valued at around $1,954,367. Citadel Advisors LLC also saw an increase, adding 259,450 shares (+563.4%) during the same period, amounting to $1,842,095. Conversely, Archon Capital Management LLC eliminated 143,968 shares (-100.0%) from their portfolio, representing $1,022,172.

Regarding analyst ratings, Wall Street has been active in issuing reports on $CVRX in recent months, with 1 firm issuing buy ratings and none issuing sell ratings. For instance, Canaccord Genuity released a “Buy” rating on 11/06/2025, contributing to the overall sentiment surrounding the stock.

Multiple analysts have also provided price targets for $CVRX, with 2 analysts presenting estimates in the last 6 months. The median target stands at $11.5, with William Plovanic from Canaccord Genuity setting a target price of $10.0 on 02/13/2026 and Ross Osborn from Cantor Fitzgerald setting a target price of $13.0 on 11/06/2025.

It is important to note that the information provided in this article is not financial advice and should be treated as such. To access further details and disclaimers, readers are encouraged to visit Quiver Quantitative’s website for more information on this subject.